The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.

  • Stephen C. Woods
  • Published 2007 in
    JAAPA : official journal of the American Academy…


Although rimonabant has been approved for use in several countries, the Food and Drug Administration has expressed concern about the potential for adverse neurologic and psychiatric effects, considering the widespread distribution of CB1 receptors in the brain. While more research is clearly needed, the clinical evidence shows that CB1-receptor blockade… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics